topotecan has been researched along with urea in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ashwell, S; Caleb, BL; Deng, C; Green, S; Grondine, MR; Haye, HR; Horn, CL; Janetka, JW; Liu, D; Mouchet, E; Queva, C; Ready, S; Rosenthal, JL; Schwartz, GK; Sheehy, AM; Taylor, KJ; Tse, AN; Walker, GE; White, AM; Zabludoff, SD | 1 |
| Babich, JW; Mairs, RJ; Nixon, C; Rae, C; Tesson, M | 1 |
2 other study(ies) available for topotecan and urea
| Article | Year |
|---|---|
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.
Topics: Animals; Biological Assay; Cell Cycle Proteins; Cell Death; Checkpoint Kinase 1; Deoxycytidine; DNA Damage; DNA, Neoplasm; Drug Synergism; G2 Phase; Gemcitabine; HCT116 Cells; HT29 Cells; Humans; Male; Mice; Mutation; Protein Kinase Inhibitors; Protein Kinases; Rats; Thiophenes; Topotecan; Tumor Suppressor Protein p53; Urea; Xenograft Model Antitumor Assays | 2008 |
Preliminary evaluation of prostate-targeted radiotherapy using (131) I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disulfiram; Glutamates; Humans; Imidazoles; Iodine Radioisotopes; Male; Molecular Targeted Therapy; Phthalazines; Piperazines; Prostate; Spheroids, Cellular; Thiophenes; Topotecan; Tumor Cells, Cultured; Urea | 2016 |